Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia

References

• Deininger M W, Goldman J M, Melo J V. The molecular biology of chronic myeloid leukaemia. Blood 2000; 96: 3343–3356
   PubMed Web of Science ®Google Scholar
• Lugo T G, Pendergast A M, Muller A J, Witte O N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079–1082
   PubMed Web of Science ®Google Scholar
• Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto M R, Guerrasio A, et al. Consistent amount of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996; 87: 1075–1080
   PubMed Web of Science ®Google Scholar
• Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, et al. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood 1992; 79: 997–1002
   PubMed Web of Science ®Google Scholar
• Bumm T, Muller C, Al-Ali H K, Krohn K, Sheperd P, Schmidt E, et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949
   PubMed Web of Science ®Google Scholar
• Lyon M F. Chomosomal and subchromosomal inactivation. Annual Reviews in Genetics 1968; 2: 31–52
   Google Scholar
• Allen R C, Zoghbi H Y, Mosoley A B, Rosenblatt H M, Belmont J W. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. American Journal Human Genetic 1992; 51: 1229–1239
   PubMed Web of Science ®Google Scholar
• Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga P P, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology 2005; 131: 172–179
   PubMed Web of Science ®Google Scholar
• Sessarego M, Fugazza G, Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A. Complex chromosome rearrangement may locate bcr/abl fusion gene sites other than 22q11. Haematologica 2000; 85: 35–39
   PubMed Web of Science ®Google Scholar
• Sinclair P B, Green A R, Grace C, Nacheva E P. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 395–1402
   Google Scholar
• Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti A M, Grasso R, et al. Cytogenetic and fluorescence in situ hybridization monitoring in Ph + chronic myeloid leukemia patients treated with Imatinib mesylate. Journal of Experimental & Clinical Cancer Research 2004; 23: 295–299
   PubMed Web of Science ®Google Scholar
• Maniatis T, Fritsch E, Sambrook J. Molecular cloning: a Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1989
   Google Scholar
• Kwok S, Higuchi R. Avoiding false positive with PCR. Nature 1989; 339: 237–238
   PubMed Web of Science ®Google Scholar
• Van Dongen J J, Macintyre E A, Gabert J A, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–1928
   PubMed Web of Science ®Google Scholar
• Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103: 2284–2290
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. New England Journal Medicine 2002; 346: 645–652
   PubMed Web of Science ®Google Scholar
• Serrano J, Roman J, Sanchez J, Jimenez A, Castillejo J A, Herrera C, et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukaemia: increased mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood 2000; 95: 2659–2665
   PubMed Web of Science ®Google Scholar
• Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Larrayoz M J, Lahortiga I, et al. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib. Cancer Genetic and Cytogenetic 2005; 160: 22–26
   PubMed Web of Science ®Google Scholar